ArticleOncogene2022
SELENOF is a new tumor suppressor in breast cancer.
Article in Oncogene, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 33 citations in OpenAlex.
- Selenoproteins: Minute yet vital players governing cellular fate.Genes & diseases · 2026Review
- Selenium-Containing Compounds in Breast Cancer Therapy.Biological trace element research · 2026Review
- Tracing the vertebrate selenoproteome evolution reveals expansions in ray-finned fishes and convergent depletions in tetrapods.BMC genomics · 2026Article
- Anticancer selenopeptides from food sources: synthesis strategies and multitarget mechanisms.iScience · 2026Review
- Article
- Synthesis, Antitumor Activity Evaluation and Mechanistic Study of Novel Bis-Heterocyclic Chalcones Against Liver Cancer.Journal of clinical laboratory analysis · 2026Article
- Contributions of selenoproteins to breast cancer etiology and racial disparity.Cancer causes & control : CCC · 2026Article
- The selenium paradox friend or foe in breast cancer?Annals of medicine and surgery (2012) · 2025Review
- Inverted Pyramid Nanostructures Coupled with a Sandwich Immunoassay for SERS Biomarker Detection.Nanomaterials (Basel, Switzerland) · 2025Article
- Green synthesized extracts/Au complex ofHeliyon · 2024Article
- Targeting EphA2: a promising strategy to overcome chemoresistance and drug resistance in cancer.Journal of molecular medicine (Berlin, Germany) · 2024Review
- Matched analysis of circulating selenium with the breast cancer selenotranscriptome: a multicentre prospective study.Journal of translational medicine · 2023Article
- SELENOF Controls Proliferation and Cell Death in Breast-Derived Immortalized and Cancer Cells.Cancers · 2023Article
- Distinct Roles of SELENOF in Different Human Cancers.Biomolecules · 2023Review
- Article
- Selenium status and type 2 diabetes risk.Archives of biochemistry and biophysics · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidemiological evidence has indicated an inverse association between selenium status and various types of cancer, including breast cancer. Selenoproteins are the primary mediators of selenium effects in human health. We have previously reported loss of heterozygosity in breast tumor samples of the gene for one of the selenoproteins, SELENOF. The function of SELENOF remains unclear and whether SELENOF levels impact breast cancer risk or outcome is unknown. The mining of breast cancer patient databases revealed that SELENOF mRNA is significantly lower in late-stage tumor samples and lower levels of SELENOF also predict poor patient outcome from breast cancer. Genetically manipulating SELENOF in human breast cancer cells or in the murine mammary gland by overexpression, silencing or knockout impacted cell viability by affecting both proliferation and cell death. Restoring SELENOF can attenuate a number of aggressive cancer phenotypes in breast cancer cells, including clonogenic survival, and enhance the response to drugs or radiation used in breast cancer therapy. Importantly, enhancing SELENOF expression reduced in vivo tumor growth in a murine xenograft model of breast cancer. These data indicate that SELENOF is a new tumor suppressor in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.